Gilead Sciences, Inc. $GILD Stake Boosted by SageView Advisory Group LLC

SageView Advisory Group LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 159.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,940 shares of the biopharmaceutical company’s stock after buying an additional 14,715 shares during the quarter. SageView Advisory Group LLC’s holdings in Gilead Sciences were worth $2,657,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences in the third quarter worth approximately $26,000. Howard Hughes Medical Institute purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $30,000. MTM Investment Management LLC boosted its stake in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares during the period. Kilter Group LLC acquired a new position in Gilead Sciences in the 2nd quarter worth approximately $33,000. Finally, Millstone Evans Group LLC grew its position in Gilead Sciences by 58.7% during the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 118 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 1.7%

Gilead Sciences stock opened at $146.00 on Thursday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The company has a market capitalization of $181.25 billion, a price-to-earnings ratio of 21.57, a PEG ratio of 1.95 and a beta of 0.37. The company’s fifty day moving average price is $139.70 and its two-hundred day moving average price is $126.44. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same period in the previous year, the company earned $1.90 EPS. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s payout ratio is 46.68%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Jefferies initiated coverage with a Buy and $180 price target, signaling analyst confidence and implying ~23% upside from recent levels. This provides fresh institutional buy-side interest. Jefferies Starts Gilead Sciences at Buy
• Positive Sentiment: Short interest fell ~15.7% in February to ~18.45M shares (1.5% of float), lowering the potential for short-squeeze volatility and suggesting fewer immediate bearish bets against the stock. Market data on GILD short interest
• Positive Sentiment: Macro/sector tailwind: commentators including Josh Brown (Ritholtz) are bullish on large-cap biotech as a growth segment less prone to disruption, which supports investor appetite for Gilead as a defensive growth name within biotech. Josh Brown: Biotech growth stocks immune to disruption risk
• Positive Sentiment: Market opportunity: industry reports point to expansion in CD19-targeted therapies and autoimmune/oncology pipelines, which underpins the strategic rationale for Gilead’s moves to build out oncology/CAR-T capabilities. CD19 Inhibitors Market to Witness Significant Expansion
• Neutral Sentiment: Investor outreach: Gilead presented at the Barclays and Leerink healthcare conferences (transcripts available); these investor events provide detail but have not produced a clear immediate market reaction. Barclays conference transcript
• Neutral Sentiment: Recent trading: coverage roundup and prior-day outperformance show momentum, but the move may invite short-term profit-taking. Gilead Outperforms Broader Market
• Negative Sentiment: Acquisition concern: Gilead agreed to buy Arcellx for up to $7.8B at roughly a 79% premium to the pre-deal price — strategic for oncology/CAR-T scale but potentially dilutive/expensive in the near term, which can pressure sentiment and trigger selling from valuation-conscious investors. Gilead to Acquire Arcellx, Inc. for Up to $7.8 billion

Wall Street Analyst Weigh In

GILD has been the subject of a number of research analyst reports. Cantor Fitzgerald increased their target price on Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Sanford C. Bernstein reissued an “outperform” rating and set a $160.00 price target on shares of Gilead Sciences in a research report on Wednesday, February 11th. Needham & Company LLC reissued a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a research note on Monday, February 23rd. Royal Bank Of Canada raised their price objective on Gilead Sciences from $103.00 to $118.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 11th. Finally, Rothschild & Co Redburn upped their target price on Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $157.62.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total value of $463,290.00. Following the transaction, the chief financial officer directly owned 167,779 shares in the company, valued at approximately $25,910,110.97. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the transaction, the insider directly owned 120,288 shares of the company’s stock, valued at $18,577,278.72. This represents a 18.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 309,280 shares of company stock worth $43,935,470 in the last 90 days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.